Greenstone receives NIH R61 grant for cardiac fibrosis
Greenstone Biosciences has received a Catalyze R61 award from the National Heart, Lung, and Blood Institute, part of the National Institutes of Health, to fund the discovery of drug candidates targeting myocardial fibrosis and dilated cardiomyopathy in Duchenne muscular dystrophy. The R61 phase will
<p>Greenstone Biosciences has received a Catalyze R61 award from the National Heart, Lung, and Blood Institute, part of the National Institutes of Health, to fund the discovery of drug candidates targeting myocardial fibrosis and dilated cardiomyopathy in Duchenne muscular dystrophy. The R61 phase will</p>